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Abstract
Background: The purpose of this study was to determine the benefits and limitations of screening for breast
cancer using mammography.
Methods: Descriptive design with follow-up was used in the study. Data from breast cancer screening and health
insurance claim data were used. The study population consisted of all participants in breast cancer screening from
2009 to 2014. Crude detection rate, positive predictive value and sensitivity and specificity of breast cancer
screening and, incidence rate of interval cancer of the breast were calculated.
Results: The crude detection rate of breast cancer screening per 100,000 participants increased from 126.3 in 2009
to 182.1 in 2014. The positive predictive value of breast cancer screening per 100,000 positives increased from 741.2
in 2009 to 1,367.9 in 2014. The incidence rate of interval cancer of the breast per 100,000 negatives increased from
51.7 in 2009 to 76.3 in 2014. The sensitivities of screening for breast cancer were 74.6% in 2009 and 75.1% in 2014
and the specificities were 83.1% in 2009 and 85.7% in 2014.
Conclusions: To increase the detection rate of breast cancer by breast cancer screening using mammography, the
participation rate should be higher and an environment where accurate mammography and reading can be
performed and reinforcement of quality control are required. To reduce the incidence rate of interval cancer of the
breast, it will be necessary to educate women after their 20s to perform self-examination of the breast once a
month regardless of participation in screening for breast cancer.
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Background
Malignant neoplasm of the breast has a major influ-
ence on the death rate among women; it is the cancer
with the second highest incidence rate in Korean
women after malignant neoplasm of the thyroid. The
crude incidence rate of malignant neoplasm of the
breast in women increased from 24.3 persons per
100,000 population in 1999 to 65.7 persons per
100,000 population in 2012 [1].
For early detection of breast cancer, the National
Health Insurance Service (NHIS) in Korea began
screening for breast cancer using mammography and
physical examination of the breast concurrently once
every 2 years without copayment in 1999, targeting
women with medical aid who were over 40 years of
age [2]. Free screening for breast cancer was ex-
panded to include those with health insurance who
were in the lowest 20% of income in 2002, the lowest
30% in 2003, and lower 50% in 2005; currently, even
those who do not qualify for free breast cancer
screening may receive screening by paying part of the
cost (10% since 2010). The expansion of eligibility for
screening and reduction of screening cost resulted in
increases in the breast cancer screening participation
rate from 23.6% (4,437,492 individuals) in 2005 to
59.3% (5,849,134 individuals) in 2014 [3].
Recently, the committee that developed the Korean
guideline for breast cancer screening concluded that
the benefits of screening for breast cancer with mam-
mography outweighed the potential harm based on
the results of meta-analysis using the domestic and
foreign literature on death rate, total death rate, and
stage shift of breast cancer and they issued the
Korean guidelines for breast cancer screening, encour-
aging women ages 40–69 to undergo breast cancer
screening by mammography and physical examination
every 2 years [4]. However, mammography has a
number of drawbacks, including radiation exposure
[5], overdiagnosis [6], anxiety due to false positive re-
sults [7], unnecessary biopsies and surgery [8], inci-
dence of interval cancers [9], and psychological stress
[10]. In addition, some researchers insist that people
should make their own informed decision regarding
breast cancer screening based on being provided suffi-
cient information about the benefits and the potential
harm, as breast cancer screening does not have a
marked effect on the incidence of breast cancer and
death [11, 12]. Nevertheless, mammography is the
best radiological diagnostic screening tool from the
cost–effectiveness viewpoint, and many countries and
institutes encourage breast cancer screening using this
method [13].
Although research on breast cancer screening has
focused mainly on the intention and determinants of
breast cancer screening [14, 15], the distribution of
dense breast tissue and related factors in mammog-
raphy [16, 17], and comparison of mammography
and ultrasound examination [18, 19], there has been
inadequate discussion regarding the benefits and lim-
itations of breast cancer screening with mammog-
raphy. This study was performed to determine the
benefits and limitations of screening for breast can-
cer using mammography based on the detection rate,
the positive predictive value of screening for breast
cancer, and the incidence rate of interval breast
cancer.
Methods
Study design and sample
Descriptive design with follow-up was used in the
study. This study used data from breast cancer
screening with mammography from January 2009 to
December 2014, combined with health insurance
claim data on medical expenses for breast cancer
treatment from January 2002 to August 2015 ex-
tracted from the electronic data of NHIS.
The study population consisted of all participants
in breast cancer screening conducted by NHIS over
the 6 years from 2009 to 2014. Participants who had
been treated for breast cancer (malignant neoplasm
or carcinoma in situ) prior to screening were ex-
cluded. The final numbers of subjects included in
the analyses were 2,977,041 in 2009, 2,907,964 in
2010, 3,359,526 in 2011, 3,334,657 in 2012, 3,291,981
in 2013, and 3,564,681 in 2014. Screening for breast
cancer with mammography conducted by NHIS in
Korea is currently carried out for all women over
40 years of age regardless of previous breast cancer
diagnosis.
Measurement
1) Selection and processing of variables
Subjects’ ID, age, screening date, and screening
results were selected from breast cancer screening
data, and subjects’ ID, age, sex, disease code
(including 1st to 5th diagnoses), treatment methods
(anticancer drugs or operation), special case
calculation, and the date of visits to medical
institutions were selected from the health insurance
claim data.
The subjects were classified according to age at the
time of screening as 40–49, 50–59, 60–69, and
70 years or older, and the screening results were
classified as normal, benign lesion, suspected breast
cancer, and deferred. Using the disease codes in the
health insurance claim data, breast cancers were
classified as malignant neoplasms, (C50 in the
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Korean Standard Classification of Diseases) or
carcinoma in situ (D05).
The detection of breast cancer was judged
according to the use of anticancer drugs, surgery,
such as mastectomy or radical mastectomy related
to breast cancer, and special case calculations, as
described below. That is, subjects were defined as
having breast cancer if they were diagnosed with
malignant neoplasm or carcinoma in situ, received
anticancer medication related to breast cancer or
breast cancer surgery and were the subject of
special case calculation. The date of breast cancer
detection was defined as the first visit day
(hospitalization or outpatient) to a medical
institution for anticancer drugs or surgery. For
example, a breast cancer detection date of May 1,
2009, in the health insurance claim data indicated
that the patient had received no medical
treatment for breast cancer from January 1, 2002,
to April 30, 2009, at an outpatient department or
with hospitalization.
Special case calculation is a system whereby the
economic burden on patients diagnosed with
cancer, cerebrovascular and heart diseases, severe
burns, or intractable diseases is reduced by
decreasing the copayment for treatment for the
disease registered by NHIS for 5 years. This
system was introduced in July 2001; the
copayment was reduced from 20 to 10% in
September 2005, and to 5% in December 2009.
Malignant neoplasm and carcinoma in situ of the
breast are included in the criteria for special case
calculation.
2) Merging of breast cancer screening data and health
insurance claim data
Breast cancer screening data and evaluation of
insurance claim data on breast cancer were merged
according to the subjects’ ID.
3) Index for contributions and limitations of breast
cancer screening
The index for the contributions and limitations of
breast cancer screening in breast cancer detection and
the basic items for calculation are as follows:
From the results of breast cancer screening, suspected
and deferred breast cancer diagnoses were defined as
positive screening outcomes, and test results showing
normal findings and benign lesions as negative. Among
the participants in breast cancer screening, if treatment
for breast cancer occurred within 6 months from breast
cancer screening, it was defined as detection by breast
cancer screening; the absence of treatment for breast
cancer within that period was defined as non-detection.
(1)Positive rate of screening for breast cancer
The positive rate of screening for breast cancer was
defined as the number of positive tests (a + b) per
100 breast cancer screening participants (N).
Positive rate of screening for breast cancer
¼ Tested positive aþ bð Þ
Breast cancer screening participants Nð Þ  100
(2)Crude detection rate for breast cancer screening
The crude detection rate for breast cancer screening
was defined as the number of subjects with positive
test results in whom breast cancer was detected (a)
per 100,000 breast cancer screening participants (N).
Crude detection rate for breast cancer screening
¼ Tested positive and detected breast cancer að Þ
Breast cancer screening participants Nð Þ
 100; 000
(3)Positive predictive value (PPV) of breast cancer
screening
The PPV of screening for breast cancer was defined
as the number of detected breast cancer patients (a)
per 100,000 who received positive results on breast
cancer screening (a + b).
Positive predictive value of screening for breast cancer
¼ Detected breast cancer að Þ
Positive breast cancer screening aþ bð Þ
 100; 000
(4)Incidence rate of interval cancer of the breast
Cancers that occur within 12 months after negative
results on cancer screening are termed interval
cancers [20]. The incidence rate of interval cancer of
the breast was defined as the number cases of breast
cancer detected (c) among 100,000 with negative
results on the breast cancer screening (c + d).
Incidence rate of interval cancer of the breast
¼ Detected breast cancer cð Þ
Negative breast cancer screening result cþ dð Þ
 100; 000
(5)Sensitivity and specificity of screening for breast cancer
Breast cancer based on





Positive a b a + b
Negative c d c + d
Total a + c b + d N
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The sensitivity of screening for breast cancer was
defined as number of positive breast cancer screening
results (a) among 100 detected cases of breast cancer (a +
c), and the specificity of screening for breast cancer as the
number of negative results on breast cancer screening
(d) among 100 cases where breast cancer was not
detected (b + d).
Sensitivity of screening for breast cancer
¼ Positive breast cancer screening result að Þ
Detected breast cancer aþ cð Þ  100
Specificity of screening for breast cancer
¼ Negative breast cancer screening result dð Þ
Breast cancer not detected bþ dð Þ
 100
Data analysis
Data analyses were performed using SAS statistical soft-
ware (ver. 9.1, SAS Institute, Cary, NC). Using the data
of breast cancer screening and health insurance claim
data, the study subjects were selected, and the positive
rate, crude detection rate, PPV, sensitivity, and specificity
of breast cancer screening and incidence rate of interval
cancer of the breast were calculated.
Results
1. Positive rate of screening for breast cancer
The positive rate of screening for breast cancer
decreased from 17.0% in 2009 to 14.8% in 2014
(Table 1). While the positive rates for women in
their 40s and 50s during the same period decreased
from 24.7% and 17.8 to 20.1% and 15.8%,
respectively, those for women in their 60s and 70s
increased from 10.6% and 5.9 to 11.3% and 7.8%,
respectively. During all 6 years, based on women in
their 40s, the positive rate decreased as age
increased.
2. Crude detection rate of breast cancer screening
The crude detection rate of breast cancer screening
per 100,000 participants increased from 126.3 in
2009 to 182.1 in 2014 (Table 2). During the same
period, the crude detection rate of carcinoma in situ
increased from 28.0 to 42.3, and the crude detection
rate of malignant neoplasm from 98.3 to 139.8. The
crude detection rates of carcinoma in situ and of
malignant neoplasm increased in all age groups
during the same period. During all 6 years, the
crude detection rates of carcinoma in situ and of
malignant neoplasm were highest in women in their
40s and in their 50s, respectively.
Table 1 Results of screening for breast cancer with mammography from 2009 to 2014
2009 2010 2011 2012 2013 2014
No % No % No % No % No % No %
Total participants 2,977,041 100.0 2,907,964 100.0 3,359,526 100.0 3,334,657 100.0 3,291,981 100.0 3,564,681 100.0
Results of
screening
Negative Subtotal 2,469,917 83.0 2,473,581 85.1 2,874,166 85.6 2,843,801 85.3 2,817,325 85.6 3,035,615 85.2
Normal 2,163,673 87.6 2,121,346 85.8 2,465,337 85.8 2,426,471 85.3 2,378,842 84.4 2,560,714 84.4
Benign lesion 306,244 12.4 352,235 14.2 408,829 14.2 417,330 14.7 438,483 15.6 474,901 15.6
Positive Subtotal 507,124 17.0 434,383 14.9 485,360 14.4 490,856 14.7 474,656 14.4 529,066 14.8
Suspected breast
cancer
6,249 1.2 5,384 1.2 5,588 1.2 5,253 1.1 4,762 1.0 4,649 0.9
Deferred 500,875 98.8 428,999 98.8 479,772 98.8 485,603 98.9 469,894 99.0 524,417 99.1
Age 40–49 Subtotal 1,014,401 34.1 987,795 34.0 1,069,780 31.8 1,036,136 31.1 1,023,722 31.1 1,084,874 30.4
Negative 763,858 75.3 775,653 78.5 853,005 79.7 823,571 79.5 825,570 80.6 866,479 79.9
Positive 250,543 24.7 212,142 21.5 216,775 20.3 212,565 20.5 198,152 19.4 218,395 20.1
50–59 Subtotal 941,260 31.6 922,458 31.7 1,133,029 33.7 1,098,477 32.9 1,082,582 32.9 1,146,449 32.2
Negative 775,482 82.4 783,436 84.9 966,230 85.3 930,045 84.7 919,229 84.9 967,212 84.4
Positive 165,778 17.6 139,022 15.1 166,899 14.7 168,432 15.3 163,353 15.1 179,237 15.6
60–69 Subtotal 643,458 21.6 615,546 21.2 698,331 20.8 716,442 21.5 697,346 21.2 794,659 22.3
Negative 575,039 89.4 555,855 90.3 627,843 89.9 640,571 89.4 621,607 89.1 705,162 88.7
Positive 68,419 10.6 59,691 9.7 70,488 10.1 75,871 10.6 75,739 10.9 89,497 11.3
Over 70 Subtotal 377,922 12.7 382,165 13.1 458,386 13.6 483,602 14.5 488,331 14.8 538,699 15.1
Negative 355,538 94.1 358,637 93.8 427,088 93.2 449,614 93.0 450,919 92.3 496,762 92.2
Positive 22,384 5.9 23,528 6.2 31,298 6.8 33,988 7.0 37,412 7.7 41,937 7.8
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Table 2 Detection rate and positive predictive rate of screening for breast cancer with mammography from 2009 to 2014
2009 2010 2011
No. of detection % cDR PPV No. of detection % cDR PPV No. of detection % cDR PPV
Detected
breast cancer
Total 3,759 100.0 126.3 741.2 3,953 100.0 135.9 910.0 4,696 100.0 139.8 967.5
CIS 833 22.2 28.0 164.3 872 22.1 30.0 200.7 1,049 22.3 31.2 216.1
Malignant N. 2,926 77.8 98.3 577.0 3,081 77.9 106.0 709.3 3,647 77.7 108.6 751.4
Age 40–49 Subotal 1,412 37.6 139.2 563.6 1,416 35.8 143.3 667.5 1,580 33.6 147.7 728.9
CIS 353 25.0 34.8 140.9 355 25.1 35.9 167.3 393 24.9 36.7 181.3
Malignant N. 1,059 75.0 104.4 422.7 1,061 74.9 107.4 500.1 1,187 75.1 111.0 547.6
50–59 Subotal 1,344 35.8 142.8 810.7 1,476 37.3 160.0 1,061.7 1,701 36.2 150.1 1,019.2
CIS 294 21.9 31.2 177.3 330 22.4 35.8 237.4 381 22.4 33.6 228.3
Malignant N. 1,050 78.1 111.6 633.4 1,146 77.6 124.2 824.3 1,320 77.6 116.5 790.9
60–69 Subotal 728 19.4 113.1 1,064.0 744 18.8 120.9 1,246.4 1,003 21.4 143.6 1,422.9
CIS 142 19.5 22.1 207.5 142 19.1 23.1 237.9 212 21.1 30.4 300.8
Malignant N. 586 80.5 91.1 856.5 602 80.9 97.8 1,008.5 791 78.9 113.3 1,122.2
70 Subotal 275 7.3 72.8 1,228.6 317 8.0 82.9 1,347.3 412 8.8 89.9 1,316.4
CIS 44 16.0 11.6 196.6 45 14.2 11.8 191.3 63 15.3 13.7 201.3
Malignant N. 231 84.0 61.1 1,032.0 272 85.8 71.2 1,156.1 349 84.7 76.1 1,115.1
Results of screening Suspected breast cancer Subotal 1,252 33.3 – 20,035.2 1,290 32.6 – 23,959.9 1,439 30.6 – 25,751.6
CIS 225 18.0 – 3,600.6 230 17.8 – 4,271.9 271 18.8 – 4,849.7
Malignant N. 1,027 82.0 – 16,434.6 1,060 82.2 – 19,688.0 1,168 81.2 – 20,901.9
Deferred Subotal 2,507 66.7 – 500.5 2,663 67.4 – 620.7 3,257 69.4 – 678.9
CIS 608 24.3 – 121.4 642 24.1 – 149.7 778 23.9 – 162.2















Table 2 Detection rate and positive predictive rate of screening for breast cancer with mammography from 2009 to 2014 (Continued)
2012 2013 2014
No. of detection % cDR PPV No. of detection % cDR PPV No. of detection % cDR PPV
Detected
breast cancer
Total 5,324 100.0 159.7 1,084.6 5,676 100.0 172.4 1,195.8 6,493 100.0 182.1 1,367.9
CIS 1,248 23.4 37.4 254.2 1,272 22.4 38.6 268.0 1,509 23.2 42.3 317.9
Malignant N. 4,076 76.6 122.2 830.4 4,404 77.6 133.8 927.8 4,984 76.8 139.8 1,050.0
Age 40–49 Subotal 1,805 33.9 174.2 849.2 1,836 32.3 179.3 926.6 2,125 32.7 195.9 973.0
CIS 479 26.5 46.2 225.3 448 24.4 43.8 226.1 570 26.8 52.5 261.0
Malignant N. 1,326 73.5 128.0 623.8 1,388 75.6 135.6 700.5 1,555 73.2 143.3 712.0
50–59 Subotal 1,909 35.9 173.8 1,133.4 2,124 37.4 196.2 1,300.3 2,370 36.5 206.7 1,322.3
CIS 465 24.4 42.3 276.1 485 22.8 44.8 296.9 533 22.5 46.5 297.4
Malignant N. 1,444. 75.6 131.5 857.3 1,639 77.2 151.4 1,003.3 1,837 77.5 160.2 1,024.9
60–69 Subotal 1,098 20.6 153.3 1,447.2 1,091 19.2 156.5 1,440.5 1,371 21.1 172.5 1,531.9
CIS 222 20.2 31.0 292.6 223 20.4 32.0 294.4 286 20.9 36.0 319.6
Malignant N. 876 79.8 122.3 1,154.6 868 79.6 124.5 1,146.0 1,085 79.1 136.5 1,212.3
70 Subotal 512 9.6 105.9 1,506.4 625 11.0 128.0 1,670.6 627 9.7 116.4 1,495.1
CIS 82 16.0 17.0 241.3 116 18.6 23.8 310.1 120 19.1 22.3 286.1
Malignant N. 430 84.0 88.9 1,265.2 509 81.4 104.2 1,360.5 507 80.9 94.1 1,209.0
Results of screening Suspected breast cancer Subotal 1,624 30.5 - 30,915.7 1,655 29.2 - 34,754.3 1,803 27.8 - 37,862.2
CIS 307 18.9 - 5,844.3 289 17.5 - 6,068.9 310 17.2 - 6,509.9
Malignant N. 1,317 81.1 – 25,071.4 1,366 82.5 – 28,685.4 1,493 82.8 – 31,352.4
Deferred Subotal 3,700 69.5 – 761.9 4,021 70.8 – 855.7 4,690 72.2 – 998.1
CIS 941 25.4 – 193.8 983 24.4 – 209.2 1,199 25.6 – 255.2
Malignant N. 2,759 74.6 – 568.2 3,038 75.6 – 646.5 3,491 74.4 – 742.9
cDR crude detection rate, those who were tested positive and detected breast cancer patients among 100,000 breast cancer screening participants, PPV Positive predictive value, the detected breast cancer patient















3. PPV of screening for breast cancer
The PPV of breast cancer screening per 100,000
positives increased from 741.2 in 2009 to 1,367.9 in
2014 (Table 2). During the same period, the PPV of
carcinoma in situ increased from 164.3 to 317.9, and
the PPV of malignant neoplasm increased from
577.0 to 1,050.0. The PPV of carcinoma in situ and
of malignant neoplasm increased in all age groups
during the same period. During all 6 years, the PPV
of carcinoma in situ and of malignant neoplasm
were highest in women in their 50s and in their 60s,
respectively.
In breast cancer screening, the PPV of suspected
breast cancer increased from 20,035.2 in 2009 to
37,862.2 in 2014, and the PPV of cases classified as
deferred increased from 500.5 to 998.1 during the
same period.
4. Incidence rate of interval cancer in breast cancer
screening
The incidence rate of interval cancer of the breast
per 100,000 negatives increased from 51.7 in 2009 to
76.3 in 2014 (Table 3). During the same period, the
incidence rate of interval carcinoma in situ increased
from 9.9 to 17.8, and that of interval malignant
neoplasm increased from 41.8 to 58.5. The incidence
rates of interval carcinoma in situ and of interval
malignant neoplasm increased in all age groups
during the same period. During all 6 years, the
incidence rates of both interval carcinoma in situ
and of interval malignant neoplasm were highest in
women in their 40s.
Based on the results of breast cancer screening, the
incidence rate of interval breast cancer from the
normal increased from 35.4 in 2009 to 56.0 in 2014.
During the same period, the incidence rate of
interval breast cancer from the benign lesions
increased from 167.5 to 186.8.
5. Sensitivity and specificity of screening for breast
cancer
From 2009 to 2014, the sensitivities of screening for
breast cancer were 74.6, 74.1, 72.3, 73.6, 74.1, and
75.1%, respectively, and the specificities were 83.1,
85.2, 85.7, 85.4, 85.7, and 85.7%, respectively
(Table 4).
Discussion
This study was performed to evaluate the contributions
and limitations of breast cancer screening with mam-
mography based on the detection rate and PPV of
screening for breast cancer and the incidence rate of
interval breast cancer.
The crude detection rate of breast cancer screening,
i.e., the crude detection rate of carcinoma in situ and
malignant neoplasm, is increasing every year. On the
other hand, the crude detection rate of malignant neo-
plasm of the breast in this study was about 7.0 –15.0%
higher than that per 100,000 women over 40 in the data
of the Central Cancer Registry (91.8 in 2009, 94.9 in
2010, 104.3 in 2011, and 106.3 in 2012) [1]. The detec-
tion rates of screening for breast cancer (including inva-
sive breast cancer and ductal carcinoma in situ)
employing mammography in 1996–2009 for the Breast
Cancer Surveillance Consortium (BCSC) in the USA and
Copenhagen and Funen in Denmark were 4.3, 6.8, and
5.8 per 1000 female screening participants, respectively.
Although there were some differences in survey time,
these values were 4.4–6.7 times higher than those that
detected in Korea in 2009 [21]. However, the detection
rate of screening for breast cancer is influenced by the
incidence of breast cancer, the age of screening partici-
pants, and the sensitivity and specificity of screening
tools for breast cancer, so assessing validity based on
simple comparisons has some limitations. For example,
the age-standardized incidence rates of breast cancer per
100,000 breast cancer screening participants in the USA
and Denmark in 2012 among women 50– 69 years old
were 92.9 and 105.0, respectively, which were 2.1 and
2.3 times higher, respectively, than the incidence rate
(44.7) in Korea. The ages of breast cancer screening par-
ticipants were 50–69 in Denmark and 51–74 in the
USA. This limited participants to the age group with
relatively high incidence rates of breast cancer, but
screening for breast cancer conducted by NHIS targeted
all women over 40 [21]. The differences in sensitivity
and specificity of screening for breast cancer are dis-
cussed below.
The PPV of suspected breast cancer increased from
20.0% in 2009 to 37.9% in 2014, and that of cases classified
as deferred increased from 0.5 to 1.0% during the same
period. According to the guidelines on reporting results
and recommendations of the Korea National Cancer
Screening Program, deferred cases are those in which a
judgment of normal, benign lesion, or suspected cancer
cannot be made based only on the present examination,
and additional examinations, such as ultrasound or mag-
nified views, comparison with previous mammograms, or
re-examination after some period is recommended for ac-
curate diagnosis. To overcome the limitation of the mam-
mography and increase PPV of breast cancer screening,
some technique using infrared thermography was intro-
duced. For example, Gerasimova-Chechkina et al. [22]
showed combining sparse and sometimes painful and
quite uncomfortable mammography examinations with
more frequent inexpensive, quick and painless infrared
thermography examinations could become a very efficient
routine breast cancer. For suspected breast cancer, biopsy
within a short period is recommended for definite diagno-
sis [23]. Among the deferred cases, the rates of those
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Table 3 Incidence rate of breast interval cancer from 2009 to 2014
2009 2010 2011 2012 2013 2014
No. of
incidence
% IR No. of
incidence
% IR No. of
incidence
% IR No. of
incidence
% IR No. of
incidence





Total 1,278 100.0 51.7 1,385 100.0 56.0 1,801 100.0 62.7 1,912 100.0 67.2 1,986 100.0 70.5 2,150 100.0 76.3
CIS 245 19.2 9.9 259 18.7 10.5 392 21.8 13.6 436 22.8 15.3 446 22.5 15.8 501 23.3 17.8
Malignant
N.
1,033 80.8 41.8 1,126 81.3 45.5 1,409 78.2 49.0 1,476 77.2 51.9 1,540 77.5 54.7 1,649 76.7 58.5
Age 40–49 Subtotal 608 47.6 79.6 678 49.0 87.4 802 44.5 94.0 852 44.6 103.5 914 46.0 110.7 975 45.3 112.5
CIS 111 18.3 14.5 134 19.8 17.3 170 21.2 19.9 193 22.7 23.4 213 23.3 25.8 229 23.5 26.4
Malignant
N.
497 81.7 65.1 544 80.2 70.1 632 78.8 74.1 659 77.3 80.0 701 76.7 84.9 746 76.5 86.1
Subtotal 456 35.7 58.8 469 33.9 59.9 691 38.4 71.5 665 34.8 71.5 690 34.7 75.1 787 36.6 81.4
50–59 CIS 89 19.5 11.5 87 18.6 11.1 154 22.3 15.9 163 24.5 17.5 142 20.6 15.4 182 23.1 18.8
Malignant
N.
367 80.5 47.3 382 81.4 48.8 537 77.7 55.6 502 75.5 54.0 548 79.4 59.6 605 76.9 62.6
Subtotal 161 12.6 28.0 181 13.1 32.6 225 12.5 35.8 291 15.2 45.4 285 14.4 45.8 296 13.8 42.0
60–69 CIS 36 22.4 6.3 32 17.7 5.8 55 24.4 8.8 61 21.0 9.5 77 27.0 12.4 65 22.0 9.2
Malignant
N.
125 77.6 21.7 149 82.3 26.8 170 75.6 27.1 230 79.0 35.9 208 73.0 33.5 231 78.0 32.8
Subtotal 53 4.1 14.9 57 4.1 15.9 83 4.6 19.4 104 5.4 23.1 97 4.9 21.5 92 4.3 18.5
70 CIS 9 17.0 2.5 6 10.5 1.7 13 15.7 3.0 19 18.3 4.2 14 14.4 3.1 25 27.2 5.0
Malignant
N.
44 83.0 12.4 51 89.5 14.2 70 84.3 16.4 85 81.7 18.9 83 85.6 18.4 67 72.8 13.5
Subtotal 765 59.9 35.4 813 58.7 38.3 1,050 58.3 42.6 1,136 59.4 46.8 1,195 60.2 50.2 1,331 61.9 56.0
Results of
screening
Normal CIS 129 16.9 6.0 152 18.7 7.2 208 19.8 8.4 246 21.7 10.1 253 21.2 10.6 314 23.6 13.2
Malignant
N.
636 83.1 29.4 661 81.3 31.2 842 80.2 34.2 890 78.3 36.7 942 78.8 39.6 1,017 76.4 42.8
Benign
lesion
Subtotal 513 40.1 167.5 572 41.3 162.4 751 41.7 183.7 776 40.6 185.9 791 39.8 180.4 819 38.1 186.8
CIS 116 22.6 37.9 107 18.7 30.4 184 24.5 45.0 190 24.5 45.5 193 24.4 44.0 187 22.8 42.6
Malignant
N.
397 77.4 129.6 465 81.3 132.0 567 75.5 138.7 586 75.5 140.4 598 75.6 136.4 632 77.2 144.1















treated for breast cancer within 6 months after screening
were 0.5 in 2009 and 1% in 2014. For accurate diagnosis,
deferred cases should be recommended to undergo add-
itional measures, such as re-examination after 2 months
or immediate ultrasound examination of the breast.
However, there have been no previous reports regarding
the rates at which screening recipients underwent which
types of additional measures after receiving a deferred
judgment.
This study showed that the incidence rate of interval
cancer per 10,000 negative (normal, benign lesions) re-
sults on screening for breast cancer increased from 5.2
persons in 2009 to 7.8 persons in 2014; especially, the
incidence rate of malignant neoplasm of the breast dur-
ing the same period increased from 4.2 persons to 5.7
persons. With the interval cancer incidence period set to
1 year after screening, the incidence rate of interval can-
cer of breast cancer increased from 8.5 to 10.1, and that
of malignant neoplasm of the breast increased from 6.9
to 7.8 (not shown in the Results section). There are five
possible reasons why interval cancer may occur [24].
First, no sign of disease may be detected on previous
screening mammogram; the lesion is new (true negative
interval cancer). Second, a lesion that proves to be ma-
lignant showed benign morphological characteristics on
the previous mammogram (benign interval cancer).
Third, a now-known lesion is seen on the previous
screen mammogram; this is an interpretive error on the
part of the reader (retrospectively visible interval can-
cer). Fourth, a second reader may discover the lesion
(single reader interval cancer); second reads in screening
programs yield up to a 10% increase in cancer detection.
Breast cancer is diagnosed based on the architectural
distortion, asymmetric density and irregular, speculated
margins with clustered calcification on the mammogram
by one radiologist who has the certificate for reading the
mammogram in Korea [23]. In order to overcome the
limitation of the reading by one radiologist, it is pro-
posed to use the use computer-aided diagnostic (CAD)
methods. Some studies introduced its strength [25] and
showed its use during screening mammography in-
creased the incidence of ductal carcinoma in situ, the
diagnosis of invasive breast cancer at earlier stages, and
increased diagnostic testing among women without
breast cancer [26].
Fifth, a technically poor image may prevent the reader
from discovering the abnormality; in theory, suboptimal
images should not be submitted for interpretation, and
those that are submitted should not be read (technical
failure interval cancer). Among the 240 diagnosed inter-
val breast cancers in Korea, 78 (32.5%) were classified as
true interval breast cancer in which previous screening
showed no signs of breast cancer, and the cancer had
newly occurred; 78 (32.5%) as minimal signs; and 84
(35%) as missed interval breast cancer, where there was
a suspicion of breast cancer, but the cancer could not be
Table 4 Sensitivity and specificity of screening for breast cancer with mammography from 2009 to 2014




2009 Positive 3,759 74.6 503,365 507,124
Negative 1,278 2,468,639 83.1 2,469,917
Total 5,037 2,972,004 2,977,041
2010 Positive 3,953 74.1 430,430 434,383
Negative 1,385 2,472,196 85.2 2,473,581
Total 5,338 2,902,626 2,907,964
2011 Positive 4,696 72.3 480,664 485,360
Negative 1,801 2,872,365 85.7 2,874,166
Total 6,497 3,353,029 3,359,526
2012 Positive 5,324 73.6 485,532 490,856
Negative 1,912 2,841,889 85.4 2,843,801
Total 7,236 3,327,421 3,334,657
2013 Positive 5,676 74.1 468,980 474,656
Negative 1,986 2,815,339 85.7 2,817,325
Total 7,662 3,284,319 3,291,981
2014 Positive 6,493 75.1 468,163 474,656
Negative 2,150 2,815,175 85.7 2,817,325
Total 8,643 3,283,338 3,564,681
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detected [27]. As the first two of the five types of inter-
val cancer are limitations of the screening procedure it-
self and the remaining three types of interval cancer of
the breast could have been detected at the time of
screening, active quality control of the equipment and
facility used for mammography, mammograms, and
reading is required.
NHIS conducts quality control by introducing
guidelines and performing periodic checkups on the
human resources, equipment, facilities, and environ-
ments [28], as well as providing diverse types of edu-
cation aimed at the radiologists and radiology
technicians who read the results [29]. Previously, the
incidence rates of interval cancer of the breast re-
ported by BCSC in the USA and in Copenhagen and
Funen, Denmark, were 9, 8, and 8 per 10,000 screen-
ing participants, respectively [21].
Finally, the sensitivities and specificities of screening
for breast cancer using mammography did not
change, with values of 74.5 and 83.1% in 2009, and
75.1% and 85.7% in 2014, respectively. Previously, the
sensitivity for participants undergoing breast cancer
screening for the first time were 91.8% for the BCSC,
90.5% in Copenhagen, and 92.5% in Funen, and the
sensitivities for participants undergoing breast cancer
screening more than twice were 82.3, 88.9, and 86.9%,
respectively. The specificities for participants undergo-
ing breast cancer screening for the first time were
83.2, 96.6, and 97.9%, respectively, while those for
participants who underwent breast cancer screening
more than twice were 91.6, 98.8, and 99.2%, respect-
ively [21]. In comparing the sensitivities and specific-
ities of screening for breast cancer according to
breast-cancer related symptoms (none, meaningful
symptoms, and other symptoms) prior to screening in
Australia, the sensitivity and specificities for the
screening group without symptoms were 75.6 and
94.9%, respectively, those for the screening group with
meaningful symptoms were 80.8 and 73.7%, respect-
ively, and those in the screening group with other
symptoms were 60.0 and 95.4%, respectively [30].
Generally, mammography shows lower sensitivity in
younger subjects and in those with dense breast tis-
sue. In a study comparing parenchyma and sensitivity,
the sensitivity in subjects over 50 years old decreased
from 98.4% in participants with fatty breast tissue to
83.7% in those with dense breast tissue, and the sen-
sitivity of the high-risk group with dense breast tissue
decreased to 68.8% [31, 32].
The principal goal of breast cancer screening is to re-
duce breast cancer mortality and morbidity. Many coun-
tries monitor the individual steps throughout the entire
screening process in order to ensure that the objectives
of a successful breast cancer screening program with
some performance indicators such as participation rate,
retention rate, diagnostic interval etc. [33–35]. However,
there is no formal guideline for monitoring breast
screening program performance in Korea. This study
would be a milestone to develop the Korean version for
the guideline for monitoring breast screening program
performance.
This study had a number of limitations. First, as
health insurance claim data were used to detect
breast cancer in the Central Cancer Registry, there
may have been some differences between the actual
incidences of breast cancer in the Central Cancer
Registry and the cases detected in this study. In fact,
the data of the Central Cancer Registry included de-
ceased subjects, and the data from the present study
excluded end stage breast cancer patients who re-
ceived only palliative treatment with no anticancer
treatment or surgery. However, the number of de-
tected malignant neoplasms of the breast ranged from
97.3 to 101.1% of the value given by the Central Can-
cer Registry data during 2009 to 2012. In addition, as
most cancer patients qualified for special case calcula-
tion, the difference between the number of the de-
tected breast cancers in this study and the number in
the Central Cancer Registry was unlikely to be large
enough to significantly influence our results. Second,
the detection of breast cancer may be influenced by
symptoms, participation in screening, and level of expos-
ure to risk factors such as pregnancy, breast feeding, and
hormone treatment, etc. However, these factors were not
taken into consideration in this study. We attempted to
reduce the possibility of detection due to factors other
than screening for breast cancer conducted by NHIS by
limiting the period of detection of breast cancer to within
6 months after screening.
Conclusions
For breast cancer screening using mammography to
play a role in detecting breast cancer, the participa-
tion rate, especially for women in their 40s and 50s,
should be higher. In addition, an environment where
accurate mammography and reading can be per-
formed, and reinforcement of quality control are
required. Appropriate guidelines for deferred deter-
mination (e.g., coverage of ultrasound examination by
insurance in cases of deferred determination) should
be prepared. To reduce the incidence rate of interval
cancer of the breast, it will be necessary to educate
women after their 20s to perform self examination of
the breast once a month regardless of participation in
screening for breast cancer.
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